Status:

TERMINATED

Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit

Lead Sponsor:

Medical University of Vienna

Conditions:

Critical Illness

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Platelets play a central part not just in homeostasis and thrombosis as the primary effector cells, but they are also key cells in the regulation of the immunological response to various stressors. Af...

Eligibility Criteria

Inclusion

  • patients admitted to an intensive care unit
  • \>18 years of age

Exclusion

  • known allergy of intolerance to acetylsalicylic acid
  • recent surgery or planned surgery
  • active bleeding
  • known coagulation disorders
  • discretion of the physician
  • terminal illness (anticipated life expectancy \<3months; e.g. due to cancer)
  • platelet count \<20 000
  • recent ulcera
  • recent gastrointestinal bleeding
  • pregnancy

Key Trial Info

Start Date :

November 15 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 10 2017

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT02285153

Start Date

November 15 2011

End Date

November 10 2017

Last Update

December 18 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

General Hospital

Vienna, Austria, 1090

Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit | DecenTrialz